Bioline RX Ltd Sponsored ADR Stock News
$3.55
2.20%
yesterday
Nasdaq,
Sep 04, 10:00 pm CET
Bioline RX Ltd Sponsored ADR Stock News
Neutral
Seeking Alpha
●
21 days ago
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.
Neutral
PRNewsWire
●
22 days ago
- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel , Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX),...
Neutral
PRNewsWire
●
29 days ago
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.
Neutral
MarketBeat
●
3 months ago
Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.
Neutral
PRNewsWire
●
3 months ago
- 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31 st TEL AVIV, Israel , May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilo...
Neutral
Seeking Alpha
●
3 months ago
BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2025 Earnings Conference Call May 27, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - H.C.
Neutral
PRNewsWire
●
3 months ago
- Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting – - APHEXDA performing well under Ayrmid stewardship - - Man...
Neutral
PRNewsWire
●
4 months ago
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , May 20, 2025 /PRNewswire/ -- BioLineRx Ltd.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
